Post-transfusion hepatitis and liver dysfunction are common in hemophilia patients receiving Factor VIII concentrate. Treatment regimens and concentrate amounts did not impact disease incidence, highlighting the need for close monitoring.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: